Subsequent results validated that THF alleviates glucose intolerance and hepatic steatosis by targeting AKT- (protein kinase B-) SREBP (sterol regulatory element-binding protein) nexus through activating PI3K (phosphatidylinositol-3 kinase) and LDL-R (low-density lipoprotein receptor) involved pathways. This evidence concerns the gene AKT1 and fatty liver disease.